CD3 epsilon subunit of T-cell receptor complex. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Blinatumomab CHEMBL1742992 |
T cell surface glycoprotein CD3 cross-linking agent Cross-linking agent Antibody |
✓ Both | 49 |
| Glofitamab CHEMBL4298092 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
ChEMBL only | 46 |
| Teclistamab CHEMBL4594505 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
ChEMBL only | 35 |
| Elranatamab CHEMBL4297809 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
ChEMBL only | 31 |
| Epcoritamab CHEMBL4650393 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
✓ Both | 26 |
| Tarlatamab CHEMBL5095292 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
✓ Both | 26 |
| Mosunetuzumab CHEMBL4297788 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
✓ Both | 20 |
| Talquetamab CHEMBL4594503 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
ChEMBL only | 20 |
| Odronextamab CHEMBL4298084 |
T cell surface glycoprotein CD3 binding agent Binding agent Antibody |
ChEMBL only | 10 |
| Teplizumab CHEMBL1743078 |
T-cell surface glycoprotein CD3 epsilon chain other Other Antibody |
✓ Both | 7 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Non-Hodgkin lymphoma | 7 | Phase 3 |
| Richter transformation | 5 | Phase 2 |
| Marginal zone lymphoma | 4 | Phase 3 |
| B-cell chronic lymphocytic leukemia | 4 | Phase 2 |
| Diffuse large B-cell lymphoma | 3 | Phase 3 |
| High grade B-cell lymphoma | 3 | Phase 3 |
| Mantle cell lymphoma | 3 | Phase 3 |
| B-cell non-Hodgkin lymphoma | 3 | Phase 2/3 |
| Burkitt lymphoma | 3 | Phase 1 |
| AL amyloidosis | 2 | Phase 2 |
| Waldenstrom macroglobulinemia | 2 | Phase 2 |
| Lupus nephritis | 2 | Phase 2 |
| Acute myeloid leukemia by FAB classification | 2 | Phase 1/2 |
| Mature T-cell and NK-cell non-Hodgkin lymphoma | 2 | Phase 1/2 |
| Myelodysplastic syndrome | 2 | Phase 1/2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
